Leveraging the effects of chloroquine on resistant malaria parasites for combination therapies

BackgroundMalaria is a major global health problem, with the Plasmodium falciparum protozoan parasite causing the most severe form of the disease. Prevalence of drug-resistant P. falciparum highlights the need to understand the biology of resistance and to identify novel combination therapies that are effective against resistant parasites. Resistance has compromised the therapeutic use of many antimalarial drugs, including chloroquine, and limited our ability to treat malaria across the world. Fortunately, chloroquine resistance comes at a fitness cost to the parasite; this can be leveraged in developing combination therapies or to reinstate use of chloroquine.ResultsTo understand biological changes induced by chloroquine treatment, we compared transcriptomics data from chloroquine-resistant parasites in the presence or absence of the drug. Using both linear models and a genome-scale metabolic network reconstruction of the parasite to interpret the expression data, we identified targetable pathways in resistant parasites. This study identified an increased importance of lipid synthesis, glutathione production/cycling, isoprenoids biosynthesis, and folate metabolism in response to chloroquine.ConclusionsWe identified potential drug targets for chloroquine combination therapies. Significantly, our analysis predicts that the combination of chloroquine and sulfadoxine-pyrimethamine or fosmidomycin may be more effective against chloroquine-resistant parasites than either drug alone; further studies will explore the use of these drugs as chloroquine resistance blockers. Additional metabolic weaknesses were found in glutathione generation and lipid synthesis during chloroquine treatment. These processes could be targeted with novel inhibitors to reduce parasite growth and reduce the burden of malaria infections. Thus, we identified metabolic weaknesses of chloroquine-resistant parasites and propose targeted chloroquine combination therapies.

[1]  P. Roepe.  PfCRT-mediated drug transport in malarial parasites. , 2011, Biochemistry.

[2]  T. Egan,et al.  Haemozoin formation. , 2008, Molecular and biochemical parasitology.

[3]  A. Cowman,et al.  Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum , 1990, Nature.

[4]  D. Goldberg,et al.  The peculiarities and paradoxes of Plasmodium heme metabolism. , 2014, Annual review of microbiology.

[5]  Jeffrey D Orth,et al.  What is flux balance analysis? , 2010, Nature Biotechnology.

[6]  P. Grellier,et al.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors lovastatin and simvastatin inhibit in vitro development of Plasmodium falciparum and Babesia divergens in human erythrocytes , 1994, Antimicrobial Agents and Chemotherapy.

[7]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[8]  M. Fry,et al.  Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). , 1992, Biochemical pharmacology.

[9]  J. Wiesner,et al.  In Vitro and In Vivo Synergy of Fosmidomycin, a Novel Antimalarial Drug, with Clindamycin , 2002, Antimicrobial Agents and Chemotherapy.

[10]  J. Kublin,et al.  Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. , 2003, The Journal of infectious diseases.

[11]  Malcolm J. McConville,et al.  BCKDH: The Missing Link in Apicomplexan Mitochondrial Metabolism Is Required for Full Virulence of Toxoplasma gondii and Plasmodium berghei , 2014, PLoS pathogens.

[12]  C. D. Fitch.  Plasmodium falciparum in Owl Monkeys: Drug Resistance and Chloroquine Binding Capacity , 1970, Science.

[13]  Jason A. Papin,et al.  Functional integration of a metabolic network model and expression data without arbitrary thresholding , 2011, Bioinform..

[14]  T. Taylor,et al.  A Longitudinal Trial Comparing Chloroquine as Monotherapy or in Combination with Artesunate, Azithromycin or Atovaquone-Proguanil to Treat Malaria , 2012, PloS one.

[15]  Jason A. Papin,et al.  Novel Plasmodium falciparum metabolic network reconstruction identifies shifts associated with clinical antimalarial resistance , 2017, BMC Genomics.

[16]  A. Chou,et al.  Ferriprotoporphyrin IX fulfills the criteria for identification as the chloroquine receptor of malaria parasites. , 1980, Biochemistry.

[17]  G. McFadden,et al.  The human malaria parasite Plasmodium falciparum possesses two distinct dihydrolipoamide dehydrogenases , 2004, Molecular microbiology.

[18]  D. Platel,et al.  Plasmodium berghei: implication of intracellular glutathione and its related enzyme in chloroquine resistance in vivo. , 1995, Experimental parasitology.

[19]  P. Chavalitshewinkoon-Petmitr,et al.  Global gene expression profiling of Plasmodium falciparum in response to the anti-malarial drug pyronaridine , 2011, Malaria Journal.

[20]  A. Cowman,et al.  Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum , 1989, Cell.

[21]  D. V. Vander Jagt,et al.  Characterization of a hemoglobin-degrading, low molecular weight protease from Plasmodium falciparum. , 1986, Molecular and biochemical parasitology.

[22]  H. Lichtenthaler,et al.  Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. , 1999, Science.

[23]  W. Milhous,et al.  Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. , 1987, Science.

[24]  J. Wootton,et al.  Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. , 2000, Molecular cell.

[25]  H. Ginsburg,et al.  Kinetics of inhibition of glutathione-mediated degradation of ferriprotoporphyrin IX by antimalarial drugs. , 1999, Biochemical pharmacology.

[26]  P. Loria,et al.  Inhibition of the peroxidative degradation of haem as the basis of action of chloroquine and other quinoline antimalarials. , 1999, The Biochemical journal.

[27]  A. Kaneko,et al.  Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. , 2003, The American journal of tropical medicine and hygiene.

[28]  P. Stephens,et al.  The structure of malaria pigment beta-haematin. , 2000, Nature.

[29]  C. Wilson,et al.  Amplification of a gene related to mammalian mdr genes in drug-resistant Plasmodium falciparum. , 1989, Science.

[30]  D. Sullivan,et al.  On the molecular mechanism of chloroquine's antimalarial action. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Warhurst.  A molecular marker for chloroquine-resistant falciparum malaria. , 2001, The New England journal of medicine.

[32]  H. Ginsburg,et al.  Heme Degradation in the Presence of Glutathione , 1995, The Journal of Biological Chemistry.

[33]  H. Ginsburg,et al.  The fate of ferriprotorphyrin IX in malaria infected erythrocytes in conjunction with the mode of action of antimalarial drugs. , 1999, Molecular and biochemical parasitology.

[34]  Achintya Mohan Goswami,et al.  Computational analysis, structural modeling and ligand binding site prediction of Plasmodium falciparum 1-deoxy-d-xylulose-5-phosphate synthase , 2017, Comput. Biol. Chem..

[35]  D. Platel,et al.  Role of glutathione in the detoxification of ferriprotoporphyrin IX in chloroquine resistant Plasmodium berghei. , 1999, Molecular and biochemical parasitology.

[36]  Daniel Machado,et al.  Systematic Evaluation of Methods for Integration of Transcriptomic Data into Constraint-Based Models of Metabolism , 2014, PLoS Comput. Biol..

[37]  G. Williams,et al.  Chloroquine inhibition of repair of DNA damage induced in mammalian cells by methyl methanesulfonate. , 1974, Mutation research.

[38]  R. Tahar,et al.  Molecular epidemiology of malaria in Cameroon. XXV. In vitro activity of fosmidomycin and its derivatives against fresh clinical isolates of Plasmodium falciparum and sequence analysis of 1-deoxy-D-xylulose 5-phosphate reductoisomerase. , 2007, The American journal of tropical medicine and hygiene.

[39]  Anne Richelle,et al.  A Systematic Evaluation of Methods for Tailoring Genome-Scale Metabolic Models. , 2017, Cell systems.

[40]  Arnish Chakraborty.  Emerging drug resistance in Plasmodium falciparum: A review of well-characterized drug targets for novel antimalarial chemotherapy , 2016 .

[41]  D. Sullivan,et al.  Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. , 1997, Annual review of microbiology.

[42]  Peter W. Stephens,et al.  The structure of malaria pigment β-haematin , 2000, Nature.

[43]  J. Rifkind,et al.  Hydrogen-peroxide-induced heme degradation in red blood cells: the protective roles of catalase and glutathione peroxidase. , 2003, Biochimica et biophysica acta.

[44]  A. Cowman,et al.  Malaria: Biology and Disease , 2016, Cell.

[45]  D Payne,et al.  Spread of chloroquine resistance in Plasmodium falciparum. , 1987, Parasitology today.

[46]  A. Vaidya,et al.  Atovaquone, a Broad Spectrum Antiparasitic Drug, Collapses Mitochondrial Membrane Potential in a Malarial Parasite* , 1997, The Journal of Biological Chemistry.

[47]  H. Ginsburg.  Progress in in silico functional genomics: the malaria Metabolic Pathways database. , 2006, Trends in parasitology.

[48]  D. Goldberg,et al.  Hemoglobin degradation in the malaria parasite Plasmodium falciparum: an ordered process in a unique organelle. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[49]  The role of peroxide in haem degradation. A study of the oxidation of ferrihaems by hydrogen peroxide. , 1978, The Biochemical journal.

[50]  C. Canfield,et al.  Atovaquone-proguanil compared with chloroquine and chloroquine-sulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. , 1999, The Journal of infectious diseases.

[51]  J. Jensen,et al.  Stage-dependent effects of chloroquine on Plasmodium falciparum in vitro. , 1983, The Journal of protozoology.

[52]  David A. Fidock,et al.  Chloroquine Resistance in Plasmodium falciparum Malaria Parasites Conferred by pfcrt Mutations , 2002, Science.

[53]  I. Gluzman,et al.  Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance. , 1987, Science.

[54]  S. Müller,et al.  Regulation of intracellular glutathione levels in erythrocytes infected with chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. , 2002, The Biochemical journal.

[55]  Ines Thiele,et al.  Computationally efficient flux variability analysis , 2010, BMC Bioinformatics.

[56]  I. Gluzman,et al.  Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase. , 1994, The EMBO journal.

[57]  Ronan M. T. Fleming,et al.  Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0 , 2007, Nature Protocols.

[58]  R. Hallett,et al.  Chloroquine/Sulphadoxine-Pyrimethamine for Gambian Children with Malaria: Transmission to Mosquitoes of Multidrug-Resistant Plasmodium falciparum , 2006, PLoS clinical trials.

[59]  W. Caughey,et al.  Mechanism of autooxidation for hemoglobins and myoglobins. Promotion of superoxide production by protons and anions. , 1982, The Journal of biological chemistry.

[60]  John C. Wootton,et al.  Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum , 2002, Nature.

[61]  D. F. Wallach,et al.  A reevaluation of the status of cholesterol in erythrocytes infected by Plasmodium knowlesi and P. falciparum. , 1984, Molecular and biochemical parasitology.

[62]  B. Chait,et al.  Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease , 1991, The Journal of experimental medicine.

[63]  Ronan M. T. Fleming,et al.  Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0 , 2007, Nature Protocols.

[64]  T. Taylor,et al.  Return of chloroquine antimalarial efficacy in Malawi. , 2006, The New England journal of medicine.

[65]  G. McFadden,et al.  The malaria parasite Plasmodium falciparum has only one pyruvate dehydrogenase complex, which is located in the apicoplast , 2004, Molecular microbiology.

[66]  Ashutosh Kumar,et al.  Molecular cloning and characterization of Plasmodium falciparum transketolase. , 2008, Molecular and biochemical parasitology.

[67]  D. Ménard,et al.  Efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, chloroquine-sulfadoxine-pyrimethamine combination, and amodiaquine-sulfadoxine-pyrimethamine combination in Central African children with noncomplicated malaria. , 2005, The American journal of tropical medicine and hygiene.

[68]  D. Fidock,et al.  Evidence for a pfcrt-associated chloroquine efflux system in the human malarial parasite Plasmodium falciparum. , 2005, Biochemistry.

[69]  John M. Pisciotta,et al.  The role of neutral lipid nanospheres in Plasmodium falciparum haem crystallization. , 2007, The Biochemical journal.